drugset / Trial / NCT04309734
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
RandomizedSequentialTriple-blindTreatment
Summary
This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics (PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in HCV-infected subjects.
Timeline
- Start
- 2021-10
- Primary completion
- 2022-06
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AT-777 | Unknown | 60 mg | Oral |
| Subject | AT-777 | Unknown | 120 mg | Oral |
| Subject | Bemnifosbuvir | Other / unclassified | 550 mg | Oral |